Directorate Change

• Robert Ghenchev, Non-Executive Director, has stepped down from the Board following his departure from Novo Holdings US

Oxford, UK - 20 October 2025: OXB (LSE: OXB), a global quality and innovation-led cell and gene therapy CDMO, today announces that Robert Ghenchev, Non-Executive Director, has stepped down from the OXB Board with immediate effect, following his departure from Novo Holdings US to pursue other opportunities.

Robert Ghenchev, outgoing Non-Executive Director of OXB, stated: "It has been a pleasure to serve on the Board of OXB, during which time the Company has made strong progress in executing its strategy and strengthening its position as a leading global pure-play cell and gene therapy CDMO. I have great confidence in the Company's leadership and wish the Board and wider team every success for the future."

• Roch Doliveux, Chair of OXB, commented: "On behalf of the Board, I would like to take this opportunity to thank Rob for his excellent contributions to the Board over the past six years, a period of significant transformation for OXB, and wish him the very best for his future."

Novo Holdings A/S, a major shareholder in OXB, has reserved the right to nominate another person to be a shareholder Director, subject to the approval of OXB's Board of Directors. OXB will provide any further update to the market in due course, as appropriate.